Dasatinib + Quercetin Frailty Trial: Physical Function Outcomes
Expert Summary
The Justice et al. (2019) D+Q frailty trial randomized 29 individuals ≥70 years with walking limitations (physical frailty) to receive D+Q (dasatinib 100 mg + quercetin 1,000 mg × 3 days over 3 weeks) or placebo. The D+Q group showed significant improvements in 400m gait speed (primary endpoint, p=0.0001), 5x chair stand time (p=0.018), and SF-36 physical function domain (p=0.036).
Key Facts
- Primary endpoint — gait speed: 400m walk time improved significantly in the D+Q group (-13% vs +2% in placebo). Gait speed is a strong predictor of mortality in older adults — even small improvements have clinically meaningful implications.
- 5x Chair stand: Rising from a chair without using hands requires lower limb strength and coordination. D+Q improved this measure significantly, suggesting improved neuromuscular function beyond simple anti-inflammatory effects.
- SF-36 physical function: Patient-reported physical function improved in D+Q group. This is a validated quality-of-life measure capturing daily activities. Placebo group showed no improvement.
- Biomarker confirmation: Post-treatment p16 mRNA in skin: reduced -29%. SA-β-Gal in adipose tissue: reduced. These confirm that the functional improvements coincide with senescent cell clearance — supporting causality rather than placebo effect.
- Duration of effect: Follow-up at 12 weeks showed maintained functional improvements in D+Q group vs baseline. This suggests senolytic treatment benefits persist well beyond the 3-week treatment window.
- Safety: No serious adverse events in the frailty trial. Mild fatigue and headache were reported by some D+Q participants. One participant had transient platelet count reduction (grade 1) that normalized without intervention.
Recommended Products
Frequently Asked Questions
Who qualifies as physically frail?
Fried Frailty Criteria include ≥3 of: unintentional weight loss, exhaustion, low physical activity, slow gait speed (<0.8 m/sec), and weak grip strength. Pre-frailty (1–2 criteria) is a target for preventive intervention.
Should older adults take senolytics to prevent frailty?
The frailty trial provides the strongest functional outcome evidence for D+Q. For prevention (before frailty develops), natural senolytics (fisetin, quercetin) represent a lower-risk starting point. Those already frail may benefit from physician-supervised D+Q.
How does D+Q compare to exercise for frailty prevention?
Exercise is the gold standard for frailty prevention with the broadest evidence base. D+Q addresses the underlying cellular mechanism (senescent cell accumulation) that exercise cannot fully compensate for in aged individuals. Combining senolytics with a structured exercise program is the emerging best-practice protocol.
Scientific References
- Justice JN et al. Senolytics in idiopathic pulmonary fibrosis. EBioMedicine. 2019. PMID: 30616998
- Xu M et al. Senolytics improve physical function and increase lifespan in old age. Nature Medicine. 2018. PMID: 29988130